A look at the shareholders of Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) can tell us which group is most powerful. Insiders often own a large chunk of younger, smaller, companies while huge companies ...
Results support advancement of 10 mg dose into Phase 3 development –– End-of-Phase 2 meeting request accepted by U.S. FDA; partnership ...
Lexicon Pharmaceuticals has made progress in getting its lead drug Inpefa onto formularies and securing reimbursement agreements with insurers. Multiple studies support the cost efficacy of Inpefa for ...
Lexicon's stock rose 60% after securing a potential $1 billion deal with Novo Nordisk for the preclinical obesity drug LX9851. The company abandoned its underperforming heart failure drug and shifted ...
Lexicon Pharmaceuticals (LXRX) is expected to deliver a year-over-year decline in earnings on lower revenues when it reports results for the quarter ended December 2019. This widely-known consensus ...
An explosion in data volumes, proliferation of platforms, and evolving regulatory requirements has made effective monitoring of employee communications much more difficult. The remote and hybrid ...
A downgrade from an analyst might have something to do with it. The company did not report any news today, but we can probably attribute these losses to two factors. First, it is plausible that some ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback